FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
(NASDAQ: JAGX) Delayed: 2.56 -0.05 (1.92%)
Previous Close $2.61    52 Week High $4.60 
Open $2.50    52 Week Low $0.81 
Day High $2.64    P/E N/A 
Day Low $2.46    EPS $0.00 
Volume 102,642